HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SRPT
Sarepta Therapeutics, Inc.
SRPT lost money over the past year, so it has no meaningful PE right now. Analysts expect a turn to a loss, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SRPT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Healthy | |
| Weak |
SRPT's cash flow is currently healthy, and its profitability is stable, but its revenue and balance sheet are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SRPT PE Valuation
SRPT has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over SRPT on the outlook, with more favorable revenue and profitability expectations.
SRPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect SRPT's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over SRPT on earnings, with more consistent year-over-year improvement.
SRPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | +$1.58 |
| Q2 2026 | -$2.90 | -$2.09 |
| Q1 2026 | -$0.96 | +$1.67 |
| Q4 2025 | -$8.44 | -461% |
| Q3 2025 | -$2.95 | -288% |
| Q2 2025 | -$0.81 | -205% |
| Q1 2025 | -$2.63 | -712% |
| Q4 2024 | $2.34 | +$8.14 |
SRPT is still losing money, but far less than before: $1.37 per share over the past year, against $12.69 at its worst in early 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SRPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SRPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $381.4M | -4.5% |
| Q2 2026 | $401.3M | -34% |
| Q1 2026 | $730.8M | -1.9% |
| Q4 2025 | $442.9M | -33% |
| Q3 2025 | $399.4M | -15% |
| Q2 2025 | $611.1M | +68% |
| Q1 2025 | $744.9M | +80% |
| Q4 2024 | $658.4M | +66% |
SRPT's revenue has slid since its 2025 peak: $381M last quarter, down 4.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.4% | +24 points |
| Q2 2026 | 3.3% | -16 points |
| Q1 2026 | 49% | +89 points |
| Q4 2025 | -93% | -118 points |
| Q3 2025 | -26% | -31 points |
| Q2 2025 | 19% | +19 points |
| Q1 2025 | -40% | -49 points |
| Q4 2024 | 25% | +18 points |
SRPT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SRPT on cash flow, with more consistent year-over-year improvement.
SRPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $57M | +$94.6M |
| Q2 2026 | $196.5M | -14% |
| Q1 2026 | -$204.8M | +$422.3M |
| Q4 2025 | $127.6M | +136% |
| Q3 2025 | -$37.5M | +$70.4M |
| Q2 2025 | $229.5M | +$243.8M |
| Q1 2025 | -$627.1M | -$352.6M |
| Q4 2024 | $54M | +$127.7M |
SRPT's free cash flow has turned positive after six years mostly in the red: $176M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SRPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SRPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +499K shares |
| 1 year | +5.7% | +5.7M shares |
| 3 years | +19% | +17M shares |
| 5 years | +36% | +28M shares |
SRPT has 106M diluted shares, up 5.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over SRPT on leverage, with a lower net debt burden relative to earnings.
SRPT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 89.5x | High |
| Q2 2025 | -12.7x | Net Cash |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | 8.6x | High |
| Q2 2024 | 10.8x | High |
SRPT's net debt is more than 20 years of its operating earnings (EBITDA), up from 11 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SRPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.3 | Neutral |
| Stochastic | 26.2 | Neutral |
SRPT's weekly RSI is 42 (neutral) and its Stochastic is 26 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SRPT PE vs Healthcare Sector
| Metric | SRPT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SRPT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SRPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.7 | 9.3% below |
| 20 week MA | $18.2 | 12% below |
| 50 week MA | $18.9 | 15% below |
| 100 week MA | $35.3 | 55% below |
| 200 week MA | $78.9 | 80% below |
SRPT is in a downtrend: it's below all five of its weekly moving averages, and 80% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SRPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $129.8 | $175.0 | +35% |
| 2021 | $175.0 | $91.6 | -48% |
| 2022 | $91.6 | $130.0 | +42% |
| 2023 | $130.0 | $96.4 | -26% |
| 2024 | $96.4 | $121.5 | +26% |
| 2025 | $121.5 | $22.1 | -82% |
| 2026 YTD | $22.1 | $16.0 | -28% |
SRPT has the edge over HIMS on returns for 2026, with the stronger performance.